Sep 04, 2020 The US Food and Drug Administration has issued a warning letter to Mylan Laboratories Limited's plant in Telangana for significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API). USFDA in their letter dated…
Recent Post
- CDSCO Notifies Final Guidance Document on Medical Device Software (MDSW)
- When a “+” Sign Isn’t Just a Plus
- DCC intends to tighten control on manufacturing and supply of printed packaging materials used for drugs
- High-Alcohol Oral Formulations Move Into Schedule H1
- DCC Recommends Comprehensive Regulatory Mechanism to Curb Unapproved Drugs and FDCs
